Cargando…

Body Composition Variables as Radiographic Biomarkers of Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors

BACKGROUND: Immune checkpoint inhibitors (ICI) have revolutionized the treatment of metastatic renal cell carcinoma (mRCC). Biomarkers for mRCC patients treated with ICI are limited, and body composition is underutilized in mRCC. We investigated the association between body composition and clinical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martini, Dylan J., Olsen, T. Anders, Goyal, Subir, Liu, Yuan, Evans, Sean T., Magod, Benjamin, Brown, Jacqueline T., Yantorni, Lauren, Russler, Greta Anne, Caulfield, Sarah, Goldman, Jamie M., Nazha, Bassel, Kissick, Haydn T., Harris, Wayne B., Kucuk, Omer, Carthon, Bradley C., Master, Viraj A., Bilen, Mehmet Asim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299332/ https://www.ncbi.nlm.nih.gov/pubmed/34307176 http://dx.doi.org/10.3389/fonc.2021.707050

Ejemplares similares

Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade
por: Olsen, T. Anders, et al.
Publicado: (2021)

Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
por: Zhuang, Tony Z, et al.
Publicado: (2022)

Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience
por: Martini, Dylan J., et al.
Publicado: (2022)

Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors
por: Brown, Jacqueline T, et al.
Publicado: (2021)

Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
por: Martini, Dylan J., et al.
Publicado: (2019)

Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors
por: Shabto, Julie M., et al.
Publicado: (2020)

Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy
por: Olsen, T. Anders, et al.
Publicado: (2022)

Durable complete response for oligometastatic renal cell carcinoma with immune checkpoint inhibition and cytoreductive nephrectomy in a Jehovah’s witness: A case report
por: Zhuang, Tony Zibo, et al.
Publicado: (2022)

Blood-Based Next-Generation Sequencing in Adrenocortical Carcinoma
por: Nazha, Bassel, et al.
Publicado: (2022)

Metastatic Clear-Cell Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors: Therapies and Ongoing Trials
por: Zhuang, Tony Zibo, et al.
Publicado: (2022)

Case Report: Exceptional Response to Nivolumab Plus Ipilimumab in a Young Woman With TFE3-SFPQ Fusion Translocation-Associated Renal Cell Carcinoma
por: Martini, Dylan J., et al.
Publicado: (2021)

Neoadjuvant Cabozantinib in an Unresectable Locally Advanced Renal Cell Carcinoma Patient Leads to Downsizing of Tumor Enabling Surgical Resection: A Case Report
por: Bilen, Mehmet A., et al.
Publicado: (2021)

Detection of Microsatellite Instability via Circulating Tumor DNA and Response to Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: A Case Series
por: Ravindranathan, Deepak, et al.
Publicado: (2021)

Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy
por: Bilen, Mehmet Asim, et al.
Publicado: (2019)

Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood
por: Carlisle, Jennifer Wilkinson, et al.
Publicado: (2022)

Symptomatic methemoglobinemia in a patient with metastatic clear cell renal cell carcinoma treated with pembrolizumab and axitinib combination therapy: a case report
por: Olsen, T. Anders, et al.
Publicado: (2021)

Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy
por: Bilen, Mehmet Asim, et al.
Publicado: (2019)

Inflammatory Markers in Cancer Immunotherapy
por: Ravindranathan, Deepak, et al.
Publicado: (2021)

Metastatic Prostate Cancer Manifesting as Cholestatic Jaundice: A Case Report and Review of the Literature
por: Ravindranathan, Deepak, et al.
Publicado: (2018)

Neoadjuvant Nivolumab and Ipilimumab for Nonmetastatic Renal Cell Carcinoma with Tumor Thrombus
por: Master, Viraj A., et al.
Publicado: (2022)

Prognostic Evaluation of Metastatic Castration Resistant Prostate Cancer and Neuroendocrine Prostate Cancer with [(68)Ga]Ga DOTATATE PET-CT
por: Bilen, Mehmet Asim, et al.
Publicado: (2022)

Ramucirumab and Docetaxel in Patients with Metastatic Urothelial Carcinoma Harboring Fibroblast Growth Factor Receptor Alterations: A Case Series and Literature Review
por: Smith, Katherine Emilie Rhoades, et al.
Publicado: (2020)

A novel preoperative inflammatory marker prognostic score in patients with localized and metastatic renal cell carcinoma
por: Sekar, Rishi R., et al.
Publicado: (2017)

Case Report: Exceptional response to nivolumab plus cabozantinib in a patient with extrarenal clear cell renal cell carcinoma
por: Jansen, Caroline S., et al.
Publicado: (2023)

The immunosuppressive phenotype of tumor-infiltrating neutrophils is associated with obesity in kidney cancer patients
por: Margaroli, Camilla, et al.
Publicado: (2020)

Bladder preserving chemoradiotherapy compared to surgery for variants of urothelial carcinoma and other tumors types involving the bladder: An analysis of the National Cancer Database
por: Janopaul-Naylor, James Robert, et al.
Publicado: (2020)

Negative enrichment of circulating tumor cells from unmanipulated whole blood with a 3D printed device
por: Chu, Chia-Heng, et al.
Publicado: (2021)

PTP1B regulates lymphocytes responses androgen deprivation
por: Arredouani, Simo, et al.
Publicado: (2014)

Major histocompatibility complex I upregulation in clear cell renal cell carcinoma is associated with increased survival
por: Sekar, Rishi R., et al.
Publicado: (2016)

Immunization with a Peptide Containing MHC Class I and II Epitopes Derived from the Tumor Antigen SIM2 Induces an Effective CD4 and CD8 T-Cell Response
por: Kissick, Haydn T., et al.
Publicado: (2014)

Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy
por: Nazha, Bassel, et al.
Publicado: (2020)

Calreticulin Mutated Essential Thrombocythemia Presenting as Acute Coronary Syndrome
por: Nazha, Bassel, et al.
Publicado: (2015)

African American and Caucasian patients with Sézary syndrome have no differences in outcomes at an ethnically diverse urban medical center
por: Martini, Dylan J., et al.
Publicado: (2022)

Data regarding covariates significantly associated with sarcopenia and varying albumin statuses in patients with renal cell carcinoma
por: Schmeusser, Benjamin N., et al.
Publicado: (2022)

Primary Non-Hodgkin’s Lymphoma of the Spine: A Case Report and Literature Review
por: Moussaly, Elias, et al.
Publicado: (2015)

Preoperative Erythrocyte Sedimentation Rate Independently Predicts Overall Survival in Localized Renal Cell Carcinoma following Radical Nephrectomy
por: Cross, Brian W., et al.
Publicado: (2012)

The Scavenger Receptor MARCO Modulates TLR-Induced Responses in Dendritic Cells
por: Kissick, Haydn T., et al.
Publicado: (2014)

Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model
por: Kersh, Anna E., et al.
Publicado: (2016)

High throughput, label-free isolation of circulating tumor cell clusters in meshed microwells
por: Boya, Mert, et al.
Publicado: (2022)

Students’ Perceptions of Peer-Organized Extra-Curricular Research Course during Medical School: A Qualitative Study
por: Nazha, Bassel, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_0noaccsjl0kcvmdiucbcmtmtt6